Dew, doing my taxes last week got me reminiscing about tagging along on your DNA short. That was my first experience with shorting and it was quite an adventure. I was seriously under water at one point, but I shorted some more at that higher level and it turned out to be quite profitable.
Wish I had been shorting some biotechs these last few months.
One last comment I would make about Zebra's excellent observations about warning signs -- patient outcomes measured by the Glasgow Coma Scale were an endpoint in most or all of Dexanabinol's trials. Professional neurologists may disagree, but I view the Glasgow scale as inherently subjective as compared to other metrics, such as visual acuity. Use of endpoints which lean subjective is another warning sign.
Market Data 
Markets 
AI
